Global Scleroderma Therapeutics Market - 2022-2029

Market Overview

Scleroderma Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.98% during the forecast period (2022-2029).

Scleroderma therapeutics, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. It causes tissue throughout the body, including the lungs and other organs, to thicken and scar. SSc-ILD is a progressive lung disease in which lung function declines over time and can be debilitating and life-threatening. ILD is the leading cause of death among people with Scleroderma Therapeutics, typically resulting from a loss of pulmonary function when the lungs cannot supply enough oxygen to the heart. Scleroderma therapeutics is major in two types: localized Scleroderma Therapeutics and systemic sclerosis (SSc).

Market Dynamics

The global scleroderma therapeutics market growth is driven by several factors, such as the rising prevalence of scleroderma, increasing screening rates of scleroderma, and growing research & development activities for drug discovery to treat the scleroderma.

The presence of ongoing research and development activities is expected to drive market growth.

The growing clinical research on the interventions for scleroderma is fueling the global market growth, for instance, according to Clinical Trials. Gov there are 19 trials active for the intervention of scleroderma examples of a few are the study on the treatment of refractory severe systemic scleroderma by injection of allogeneic mesenchymal stem cells (MSC), study sponsored by Assistance Publique - Hopitaux de Paris, a study on scleroderma lung study III - combining Pirfenidone with Mycophenolate (SLSIII) sponsored by Michael Roth and estimated to be completed by September 2022, a safety and tolerability study of AVID200 in patients with diffuse cutaneous systemic sclerosis, sponsored by Formation Biologics, a study on the benefit of Bermekimab in patients with systemic sclerosis, sponsored by Hellenic Institute for the Study of Sepsis, a phase II multi-center study of high-dose Cyclophosphamide and Antithymocyte Globulin followed by autologous hematopoietic cell transplantation with post-transplant maintenance for the treatment of systemic sclerosis sponsored and collaborated by Fred Hutchinson Cancer Center and National Cancer Institute (NCI) estimated completion is on January 31, 2025. These and many other studies on different intervention approaches for scleroderma fuel the global market growth.

The lack of curative treatment and high development cost is expected to hinder global scleroderma therapeutics market growth.

However, the scleroderma treatment market growth is expected to hinder by some factors, including lack of curative treatment, poor efficacy and efficiency of current drug regimens.

Industry analysis.

The global scleroderma therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

The Corona-Virus infection outburst has significantly affected the global scleroderma therapeutics market. Because of the COVID-19 containment protocols, most market players' supply chains crumbled, leading to a lack of raw materials and disturbing the supply and demand continuum. In addition, due to the socializing restrictions, regular healthcare checkups were difficult, leaving a vast pool of scleroderma patients undetected, negatively impacting the global scleroderma therapeutics market amidst the pandemic.

Segment Analysis

The systemic indication segment is assumed to command the scleroderma therapeutics market throughout the forecast period (2022-2029)

The systemic indication segment is expected to hold the largest share over the forecast period (2022-2029), owing to the use of high-priced immunosuppressants. Several indications, such as SSc-induced symptoms and conditions that range from interstitial lung disease to pulmonary arterial hypertension, fall under systemic scleroderma and the development of new drugs for the intervention of systemic scleroderma. For instance, on Mar 4, 2021, Genentech's Actemra became the first biologic therapy approved by the FDA for slowing the decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease. Moreover, as per ClinicalTrials.Gov, 19 interventional studies are active for systemic scleroderma, and 56 studies are recruiting for their study, which shows promising growth for the systemic scleroderma indication throughout the forecast period.

Geographical Analysis

The North American region holds the largest market share of the global scleroderma therapeutics market.

North America dominates the global scleroderma therapeutics market and accounted for the largest market share in 2021, owing to the recently developed immunosuppressants and a favorable reimbursement scenario. For instance, according to the National Scleroderma Foundation, over 300,000 Americans live with some scleroderma; as per the Scleroderma Research Foundation, about 100,000 Americans with systemic scleroderma and 200,000 with localized scleroderma. An increased systemic sclerosis incidence and prevalence have been evident in the last 50 years. Although improved diagnosis and increased survival rate can partially account for this observation, there appears to be a real increase in its incidence. In addition, the presence of favorable government regulations and funding programs, along with increasing clinical trials to enhance efficiency and new product development, are also some of the factors driving the market growth in this region over the forecast period (2022-2029).

Competitive Landscape

The market is highly fragmented, with a large number of players. Some of the major players in the market include Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc., Allergan, Inc., Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc., among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing o the global growth of the scleroderma therapeutics market. For instance, in May 2022, Pfizer agreed to acquire Biohaven. Also, on 21 April 2020, the European Commission approved Boehringer Ingelheim's nintedanib for treating systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Boehringer Ingelheim International GmbH

Overview:

Boehringer Ingelheim group is a subsidiary of C.H. Boehringer Sohn AG & Co. KG was founded in 1885 by Albert Boehringer and still fully owned by the Boehringer, Liebrecht and von Baumbach families. Boehringer Ingelheim is among the leading pharmaceutical companies and is headquartered in Ingelheim; as of 2021 has around 52,391 employees. The company deals with products addressing pulmonary diseases, metabolism disorders, immunology, oncology and central nervous system diseases.

Product Portfolio:

The product portfolio of Boehringer Ingelheim International GmbH for scleroderma therapeutics contains Ofev nintedanib esylate.

The global scleroderma therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.